CABALETTA BIO, INC. (CABA): Price and Financial Metrics
GET POWR RATINGS... FREE!
CABA Stock Price Chart Interactive Chart >
CABA Price/Volume Stats
| Current price | $1.33 | 52-week high | $14.95 |
| Prev. close | $1.26 | 52-week low | $1.17 |
| Day low | $1.21 | Volume | 79,500 |
| Day high | $1.35 | Avg. volume | 165,209 |
| 50-day MA | $1.68 | Dividend yield | N/A |
| 200-day MA | $6.33 | Market Cap | 38.54M |
CABALETTA BIO, INC. (CABA) Company Bio
Cabaletta Bio, Inc. operates as a clinical-stage biotechnology company, which engages in the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor to selectively bind and eliminate B cells that produce disease-causing autoantibodies. The company was founded by Michael C. Milone, Steven Nichtberger, and Aimee Payne in 2017 and is headquartered in Philadelphia, PA.
Latest CABA News From Around the Web
Below are the latest news stories about Cabaletta Bio Inc that investors may wish to consider to help them evaluate CABA as an investment opportunity.
Cabaletta Bio Strengthens Executive Leadership Team with Promotions of Gwendolyn Binder, Ph.D. to President of Science and Technology and Arun Das, M.D. to Chief Business OfficerPHILADELPHIA, Jan. 11, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced the promotions of Gwendolyn Binder, Ph.D. to President of Science and Technology and Arun Das, M.D. to Chief Business Officer. In these new roles, Dr. Binder and Dr. Das will continue to report to Steven Nichtberger, M.D., Chief Execu |
Cabaletta Bio to Present at the 40th Annual J.P. Morgan Healthcare ConferencePHILADELPHIA, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced that Steven Nichtberger, M.D., President and Chief Executive Officer, will present at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022 at 9:00 a.m. ET. A live webcast of the presentation will be availab |
Down 63.5% in 4 Weeks, Here's Why You Should You Buy the Dip in Cabaletta Bio, Inc. (CABA)The heavy selling pressure might have exhausted for Cabaletta Bio, Inc. (CABA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal. |
Cabaletta Bio to Present at the H.C. Wainwright BioConnect ConferencePHILADELPHIA, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced that Steven Nichtberger, M.D., President and Chief Executive Officer, will present a pre-recorded company presentation at the H.C. Wainwright BioConnect Conference, which will become available for on-demand viewing on Monday, January |
Cabaletta Bio Inc. (NASDAQ:CABA) At $4.24: What To Do?In last trading session, Cabaletta Bio Inc. (NASDAQ:CABA) saw 0.31 million shares changing hands with its beta currently measuring 0. Companys recent per share price level of $4.24 trading at $0.13 or 3.16% at ring of the bell on the day assigns it a market valuation of $128.30M. That closing price of CABAs stock is Cabaletta Bio Inc. (NASDAQ:CABA) At $4.24: What To Do? Read More » |
CABA Price Returns
| 1-mo | -8.90% |
| 3-mo | -38.99% |
| 6-mo | -88.39% |
| 1-year | -88.27% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -64.91% |
| 2021 | -69.63% |
| 2020 | -10.67% |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...